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Abstract
Background: Gallbladder cancer typically follows an aggressive course, with chemotherapy the standard of care
for advanced disease; complete remissions are rarely encountered. The epidermal growth factor receptor (EGFR) is
a promising therapeutic target but the activity of single agent oral EGFR tyrosine kinase inhibitors is low. There
have been no previous reports of chemotherapy plus an EGFR-tyrosine kinase inhibitor (TKI) to treat gallbladder
cancer or correlations of response with the mutation status of the tyrosine kinase domain of the EGFR gene.
Case presentation: A 67 year old man with metastatic gallbladder cancer involving the liver and abdominal
lymph nodes was treated with gemcitabine (1000 mg/m2) on day 1 and 8 every 21 days as well as daily erlotinib
(100 mg). After four cycles of therapy, the CA 19-9 normalized and a PET/CT showed a complete remission; this
response was maintained by the end of 12 cycles of therapy. Gemcitabine was then discontinued and single agent
erlotinib was continued as maintenance therapy. The disease remains in good control 18 months after initiation of
therapy, including 6 months on maintenance erlotinib. The only grade 3 toxicity was a typical EGFR-related skin
rash. Because of the remarkable response to erlotinib plus gemcitabine, we performed tumor genotyping of the
EGFR gene for response predicting mutations in exons 18, 19 and 21. This disclosed the wild-type genotype with
no mutations found.
Conclusion: This case report demonstrates a patient with stage IV gallbladder cancer who experienced a rarely
encountered complete, prolonged response after treatment with an oral EGFR-TKI plus chemotherapy. This
response occurred in the absence of an EGFR gene mutation. These observations should inform the design of
clinical trials using EGFR-TKIs to treat gallbladder and other biliary tract cancers; such trials should not select
patients based on EGFR mutation status.
Background
Biliary tract cancers (BTC) include carcinomas of the
gallbladder and intra- and extra-hepatic bile ducts (cho-
langiocarcinomas). Gallbladder cancer is the most com-
mon type worldwide, affectsw o m e nm o r ef r e q u e n t l y
than men and is considered to be the most aggressive
form of BTC with the shortest survival [1]. In contrast
to cholangiocarcioma, gallbladder cancer (GBC) has a
distinct molecular pathogenesis and may require a dif-
ferent therapeutic approach [1,2].
The majority of BTC present at an advanced, incurable
stage and are typically treated with chemotherapy drugs
such as 5-fluoruracil, gemcitabine and cisplatin, often in
combination. Response rates range from approximately
20-40% and median overall survivals from 8-14 months
[1]. The most notable advance in the treatment of BTC is
the result of a phase III randomized trial of gemcitabine
versus gemcitabine plus cisplatin in which the
chemotherapy doublet improved overall survival by
3.6 months [3]. In order for further advances to be made,
however, it is likely that a targeted biologic therapy will
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become the paradigm in modern oncologic therapy.
The EGFR family is a prominent target of biological
therapies against multiple epithelial malignancies. In
gastrointestinal carcinomas, monoclonal antibodies tar-
geting EGFR/EGFR-1 (cetuximab, panitumomab) and
EGFR-2 (trastuzumab) have become part of the standard
treatment armamentaria against colorectal and gastric
cancers, respectively [4,5]. In pancreatic cancer, the
combination of gemcitabine plus the oral EGFR-tyrosine
kinase inhibitor (TKI) erlotinib demonstrated a small
but statistically significant improvement in overall survi-
val compared with gemcitabine alone [6]. The data in
BTC is much more limited: single agent erlotinib
resulted in a 17% progression free survival at 6 months
in previously treated patients [7], and both a case report
[8] and an ongoing phase II trial [9] support the benefit
of adding cetuximab to chemotherapy.
Based on these data and our observation of the activ-
ity of erlotinib plus gemcitabine in a patient with refrac-
tory gallbladder cancer [10], we utilized this regimen in
the front-line setting for the patient herein presented.
We also analyzed tumor EGFR DNA for the presence of
activating mutations that predict for response to EGFR-
TKIs [11]. This analysis is the first published report cor-
relating the EGFR tyrosine kinase domain genotype with
response to an EGFR-TKI in a patient with BTC.
Case Presentation
Clinical presentation
A 67 year old man in good health presented to our emer-
gency department with right upper quadrant pain. He was
a former cigarette smoker with a medical history that
included hypertension, atrial fibrillation, and coronary
artery disease requiring angioplasty eight years before. His
medications included dlitiazem, propafenone, coumadin,
aspirin, atenolol, atorvastatin and lisinopril. Physical exam-
ination was remarkable only for right upper quadrant ten-
derness. Routine complete blood count and serum
chemistry panel were within normal limits. Ultrasound
demonstrated mobile densities in the gallbladder and a
submucosal mass. An intended laparoscopic cholecystect-
omy was converted to an open procedure due to dense
fibrosis and inflammation of the gallbladder. The gallblad-
der specimen revealed a moderately differentiated adeno-
carcinoma involving the full thickness of the gallbladder
wall with extension into the serosa and with both peri-
neural and lymphovascular invasion. One month later,
after referral to a tertiary cancer center, he underwent a
partial hepatectomy with resection of segments 4 and 5,
pelvic lymphadenectomy, common bile duct excision, and
reconstruction using a Roux-en-Y hepaticojejunostomy.
Pathology revealed residual carcinoma involving the
gallbladder bed with extension into the hepatic parench-
yma; the lymph nodes were uninvolved. No adjuvant ther-
apy was administered. Fourteen months later, computed
tomography (CT) of the abdomen showed new hepatic
metastases in segments 5 and 8. Positron emission tomo-
graphy (PET)/CT scan with 18-fluorodeoxyglucose
demonstrated the liver lesions to have SUV 6.3, a focus in
the portacaval region of SUV 13.6 and a soft tissue mass
inferior to the celiac trunk of SUV 6.0. The CA 19-9 was
48 (upper limit of normal 35 IU/mL) and CEA normal. He
remained well with no complaints of abdominal pain,
weight loss, or pruritus and the physical examination at
the initiation of chemotherapy was unremarkable.
Treatment and Response
The patient was treated in a non-protocol fashion with
fixed-dose rate gemcitabine (1000 mg/m2 administered
at 10 mg/m2 per minute) [12] on day 1 and 8 every
21 days, plus erlotinib 100 mg daily. After four cycles of
therapy, a PET/CT scan showed resolution of all FDG-
avidity and the CA 19-9 declined into the normal range
(Figures 1 and 2). After six cycles of therapy, a CT scan
showed no evidence of disease and the patient was
given a one month break from gemcitabine (erlotinib
was continued) to allow for repair of a large ventral her-
nia. The patient completed 12 cycles of combination
therapy at which point a PET/CT showed a continued
complete response of all FDG-avid disease; the CA 19-9
remained at a very low level (Figures 1 and 2).
Given the complete response of the patient’sd i s e a s et o
treatment and his desire to take a break from intravenous
treatments, further chemotherapy was stopped and he
continued single-agent erlotinib. During the six months
of maintenance erlotinb, his performance status and
quality of life were excellent. The CA 19-9 has slowly
increased, though still within the normal range. A follow-
up PET/CT after six months of erlotinib showed a loca-
lized area of FDG-activity in the portacaval region SUV
9.4, without a clear lymph node or mass seen; all other
areas, including the liver, remain without evidence of
disease recurrence.
Regarding treatment tolerance, the only grade 3 toxi-
city (National Cancer Institute Common Terminology
Criteria, version 3.0) has been an EGFR-related skin
rash on the face, chest and back that has responded well
to oral doxycycline and topical clindamycin cream.
Minor toxicities have included grade 1 fatigue, grade 2
diarrhea, grade 2 neutropenia and grade 2 anemia.
EGFR testing
For EGFR mutation analysis, tumor areas of interest were
identified, microdissected, and collected cells lysed. After
genomic DNA was purified, DNA yield was determined
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time PCR was then used to evaluate for specific mutations,
deletions and insertions in the tyrosine kinase domain of
the EGFR gene. Eight reactions containing 30 primer and
probe sets were used to target specific regions of exons
18-21 as well as the wild-type sequence. EGFR-mutation
analysis by real-time PCR for the 29 known mutations,
deletions and insertions found in exons 18-21 of the EGFR
tyrosine kinase domain revealed only the wild-type
sequence (performed by Clarient Diagnostic Services)
(Figure 3).
Assessment of EGFR gene amplification was performed
by fluorescence in situ hybridization (FISH) testing of the
tumor specimen using the EGFR-CEP (chromosome 7
Figure 1 PET scan images during treatment with erlotinib plus gemcitabine. Selected PET scan images at (a) diagnosis, (b) after 4 cycles of
therapy, and (c) after 12 cycles of therapy, demonstrating a complete response to treatment.
Figure 2 CA 19-9 levels during treatment. Graphical depiction of the decline in CA 19-9 tumor marker levels during treatment with erlotinib
plus gemcitabine and with maintenance erlotinib.
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Genzyme Genetics). This demonstrated that the EGFR
gene was not amplified (Figure 4).
Conclusion
In a recently published landmark phase III trial of cis-
platin plus gemcitabine versus gemcitabine alone for the
treatment of BTC, no complete responses were seen
among 117 gallbladder cancer patients treated [3]. Simi-
larly, in phase II trials of single-agent gemcitabine given
to gallbladder [13] and BTC patients [12], no complete
responses were observed. In a recent phase II study in
BTC of gemcitabine and oxaliplatin plus the angiogen-
esis-inhibitor bevacizumab, among 35 patients treated
there were no complete responses observed by either
PET or CT scans, despite an overall response rate of
40% [14].
We took a novel approach to the treatment of our
patient with stage IV gallbladder cancer and observed a
rarely encountered complete response by both PET/CT
and dedicated CT scans. Both the response to erlotinib
plus chemotherapy and the prolonged disease control
observed with single-agent maintenance erlotinib lead us
to conclude that erlotinib plus chemotherapy may be an
effective treatment for patients with advanced gallbladder
cancer. We can not rule out that the observed response
was due solely to treatment with gemcitabine. Yet, our
unpublished observations of patients with refractory gall-
bladder cancer who responded to erlotinib plus che-
motherapy and the rarity of complete responses to
chemotherapy reported in the literature make this seem
unlikely.
The tailored use of EGFR-TKI therapy has been pio-
neered in the area of lung cancer [15]. Patients with
Figure 3 EGFR mutation analysis. Polymerase chain reaction amplification plot of exons 18-21 demonstrating the presence of only wild-type
EGFR DNA in the patient’s tumor sample. (Performed by Clarient Diagnostic Services, Aliso Viejo, CA).
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EGFR mutation have a superior response to TKI therapy
compared with chemotherapy alone [16]. In BTC, a 13-
15% tyrosine kinase domain mutation rate has been
reported and it has been suggested that patients with
tumor associated EGFR mutations be preferentially
enrolled in clinical trials of EGFR-TKIs [17,18].
The patient with gallbladder cancer presented in this
report had a rarely encountered compete response in the
absence of a tumor associated EGFR mutation. This would
suggest that future studies of EGFR-TKI therapy plus che-
motherapy in patients with BTCs should not be restricted
to those with EGFR mutations. Since gallbladder cancer
and cholangiocarcinoma are distinct clinicopathologic
entities (despite being grouped together in most clinical
trials), it is possible that erlotinib plus chemotherapy may
be more efficacious for patients with gallbladder cancer
than those with cholangiocarcinoma. Such hypotheses can
only be tested in well-designed clinical trials.
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